SOPRANO: Macitentan in pulmonary hypertension post left ventricular assist device implantation. A prospective multi-center double-blind randomized placebo-controlled parallel group study to assess the efficacy and safety of macitentan in patients with pulmonary hypertension after left ventricular assist device implantation (Protocol AC-055-205)
Are you eligible to participate in this study?
You may be eligible for this study if you meet the following criteria:
Conditions: pulmonary hypertension
Age: Between 18 - 100 Years
Gender: Male or Female
Implantation of LVAD within 45 days
Evidence of pulmonary hypertension based on a right heart catheterization
Moderate to severe restricted lung disease
Contact the research team to learn more about this study.
Fields marked with asterisk (*) are required